Keros Therapeutics, Inc. announced that its Board of Directors has initiated a formal review process to evaluate strategic alternatives aimed at maximizing stockholder value. This comprehensive review will consider options including a sale of the company, other business combination transactions, continued investment in the pipeline, and/or a return of excess capital to stockholders.
In conjunction with this review, the Board adopted a limited-duration stockholder rights plan, commonly known as a 'poison pill,' effective immediately. This plan was enacted in response to significant and rapid accumulations of the company's common stock by several investors, including one individual investor who reported holding 11.2% of Keros' outstanding shares as of April 6, 2025.
The Rights Plan is designed to protect the interests of Keros and its stockholders by ensuring all interested parties have a fair opportunity to participate in the strategic review process. It aims to reduce the likelihood of any entity gaining control through open-market accumulation without paying an appropriate control premium to all stockholders. Keros expects to provide a preliminary update on the strategic review within 60 days.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.